abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

記事

2020年8月4日

著者:
Aljazeera

France: Sanofi charged with manslaughter in criminal case over birth defects linked to epilepsy medication

"France's Sanofi charged with manslaughter in birth defects case", 3 August 2020.

French prosecutors have indicted pharma giant Sanofi for manslaughter over birth defects linked to an epilepsy drug in a long-running case that has also seen it charged with fraud. The charges relate to the drug valproate, marketed as Depakine among other trade names, which studies say has caused disabilities in about 15,000-30,000 children whose mothers took the medicine while pregnant...research found that when pregnant women took the drug, their children had an elevated risk - between 10 to 40 percent - of congenital malformations, autism and learning difficulties.

Sanofi is facing separate charges of aggravated fraud and unintentionally causing injury in 42 cases filed by families, but insists it had warned health authorities of the drug's risks already in the 1980s...Sanofi said it has filed a legal challenge to the indictment. Under the French legal system, charges do not automatically result in a trial, as prosecutors can decide not to proceed based on a lack of evidence.

Last month, a French court ordered the state to pay thousands of euros in damages over the scandal, saying officials should have ensured the drug was not taken by pregnant women...

プライバシー情報

このサイトでは、クッキーやその他のウェブストレージ技術を使用しています。お客様は、以下の方法でプライバシーに関する選択肢を設定することができます。変更は直ちに反映されます。

ウェブストレージの使用についての詳細は、当社の データ使用およびクッキーに関するポリシーをご覧ください

Strictly necessary storage

ON
OFF

Necessary storage enables core site functionality. This site cannot function without it, so it can only be disabled by changing settings in your browser.

クッキーのアナリティクス

ON
OFF

When you access our website we use Google Analytics to collect information on your visit. Accepting this cookie will allow us to understand more details about your journey, and improve how we surface information. All analytics information is anonymous and we do not use it to identify you. Google provides a Google Analytics opt-out add on for all popular browsers.

Promotional cookies

ON
OFF

We share news and updates on business and human rights through third party platforms, including social media and search engines. These cookies help us to understand the performance of these promotions.

本サイトにおけるお客様のプライバシーに関する選択

このサイトでは、必要なコア機能を超えてお客様の利便性を高めるために、クッキーやその他のウェブストレージ技術を使用しています。